VANSEN PHARMA INC.: 10-K filed 2012-03-30

Name: VANSEN PHARMA INC.: 10-K filed 2012-03-30
Creator: VANSEN PHARMA INC.
License: https://creativecommons.org/licenses/by/4.0/

What VANSEN PHARMA INC. reported in its annual report filed 2012-03-30 (fiscal FY 2011): 18 published measures, 55 facts as tagged in accession 0001477932-12-000949.

This filing

Form: 10-K (annual report)
Filed: 2012-03-30
Fiscal period: fiscal FY 2011
Accession: 0001477932-12-000949 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All VANSEN PHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-12-31	18,766	USD
At 2010-12-31	58	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2011-12-31	117,546	USD
At 2010-12-31	108,017	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2011-12-31	-98,780	USD
At 2010-12-31	-107,959	USD
At 2009-12-31	-81,127	USD
At 2008-12-31	-54,632	USD
At 2007-12-31	-35,660	USD
At 2006-12-31	-11,455	USD
At 2005-12-31	-6,305	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2011-12-31	18,766	USD
At 2010-12-31	58	USD
At 2009-12-31	2,515	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-25,064	USD	365
2005-05-09 to 2011-12-31	-212,922	USD	2428
2010-01-01 to 2010-12-31	-31,602	USD	365
2009-01-01 to 2009-12-31	-27,577	USD	365
2008-01-01 to 2008-12-31	-24,535	USD	366
2007-01-01 to 2007-12-31	-75,233	USD	365
2006-01-01 to 2006-12-31	-22,767	USD	365
2005-05-09 to 2005-12-31	-6,144	USD	237

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-20,422	USD	365
2005-05-09 to 2011-12-31	-187,440	USD	2428
2010-01-01 to 2010-12-31	-19,907	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	39,048	USD	365
2005-05-09 to 2011-12-31	208,058	USD	2428
2010-01-01 to 2010-12-31	18,318	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-12-31	18,766	USD
At 2010-12-31	58	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	6,786	USD	365
2005-05-09 to 2011-12-31	22,449	USD	2428
2010-01-01 to 2010-12-31	5,850	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-12-31	117,546	USD
At 2010-12-31	108,017	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2011-12-31	3,988	USD
At 2010-12-31	6,007	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2011-12-31	3,441,667	shares
At 2010-12-31	3,350,000	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2011-12-31	-1,852	USD
At 2010-12-31	-1,934	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-24,982	USD	365
2005-05-09 to 2011-12-31	-214,774	USD	2428
2010-01-01 to 2010-12-31	-32,470	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-25,064	USD	365
2005-05-09 to 2011-12-31	-212,922	USD	2428
2010-01-01 to 2010-12-31	-31,602	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	7,127	USD	365
2005-05-09 to 2011-12-31	45,420	USD	2428
2010-01-01 to 2010-12-31	1,479	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-6,786	USD	365
2005-05-09 to 2011-12-31	-15,225	USD	2428
2010-01-01 to 2010-12-31	-5,850	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	27,500	USD	365
2005-05-09 to 2011-12-31	94,500	USD	2428

Inspect the source

Entity: VANSEN PHARMA INC. / CIK 0001378076
Captured: 2026-09-23 02:51 UTC
SEC response SHA-256: a4f0ed9133b6b7e9e5295515e2c8f107b3eff7e5edee25a65aab492b4189c5ca

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001378076.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))